The story of an 83-year-old undergoing complex heart surgery is not just a feel-good piece; it's a seismic shift in modern **cardiac health** and **longevity**. Why the industry won't talk about this.
The imminent human trial for cellular reprogramming isn't just about aging; it's about a radical shift in economic power. This is the true story of longevity tech.
The Greenland shark holds the secret to longevity, but the real story is the biotech gold rush this discovery triggers. Dive into the science.
The promise of an anti-ageing drug is here, but the true battle isn't biological—it's economic and ethical. Unpacking the impending longevity divide.
MIT scientists claim to rejuvenate the aged immune system. But who truly benefits from this 'longevity hack'?
New research on slowing cellular aging through mitochondria manipulation hints at a massive industry shift. The real cost is hidden.